We have previously published research about using QNZ, an inhibitor of both TNF-α and NFκB, to treat experimentally induced HCC in rats. QNZ significantly reduced the expression of inflammation, oxidative stress, and fibrosis [13]. The gene discussed is NFKB1; the disease is hepatocellular carcinoma.